A Single Blind, Randomized, Sham Controlled Study of Cranial Electrical Stimulation in Bipolar II Disorder
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Change From Baseline in Mean Beck Depression Inventory (BDI) Score at Week 2
研究概览
简要总结
The purpose of this study is to assess the antidepressant effects of Cranial Electrotherapy Stimulation (CES) in the depressed phase of bipolar II disorder.; to examine the safety of daily CES in bipolar II patients; and to examine the effects of 20 minutes of daily CES on EEG reading.
The investigators hypothesize:
- The CES will reduce symptom severity more than sham (placebo) CES.
- That CES administered for 20 minutes daily for four weeks is safe and well tolerated when treating bipolar II patients.
- That CES will shift the alpha and beta power fractions of EEG downward, and that this shift correlates with a decrease in level of anxiety and depression
详细描述
I. ABSTRACT
Cranial electrical stimulation (CES) is a non-invasive brain stimulation technology that uses a small alternating current (1-2mA) applied to the scalp to affect brain function. The strength of the current is similar to that used by transcranial direct current stimulation (tDCS); the only difference is that in the case of CES the current is alternating. CES has been FDA sanctioned for the treatment of depression, anxiety and insomnia since 1978. CES was never subjected to the level of regulatory review now required for new technologies because it was "grandfather-ed" based on a device that predated the current FDA regulations. As a consequence, although hundreds of thousands of people have been treated with CES since its development in the 1950's, claims for its effectiveness have been largely anecdotal and the studies have been hampered by poor study design and inadequate blinding. It is important to study under well-controlled conditions whether this product, already in widespread use, is truly effective. This study will examine the efficacy of CES in treating the depressive phase of bipolar II disorder using a rigorous controlled design. It will be the first study of the use of CES in bipolar II disorder, and the first well controlled study of the antidepressant effects of CES. Because CES is already clinically available and large numbers of patients have received it (usually as an at-home, self treatment), it is important to conduct a randomized controlled trial rather than to merely replicate the anecdotal reports that already exist in the literature.
II. RESEARCH PLAN
- Background and Rationale
Regulatory Status of CES
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 85 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of bipolar II disorder currently in a depressive episode (without psychotic features)
- •Pretreatment HRSD score of >/= 13 and <28 and a CGI less than or equal to
- •Between 18 and 85 years old
- •Willing to provide informed consent -
排除标准
- •Subject has a history of bipolar II disorder previously untreated with medication, or bipolar I disorder, or is in a manic or mixed episode; unipolar depression, schizophrenia, schizo-affective disorder, other (non mood disorder) psychosis, depression secondary to a medical condition, mental retardation, substance dependence or abuse within the past year (except nicotine), psychotic features in this or previous episodes, amnestic disorder, dementia or MMS (mini mental exam) less than or equal to 24, delirium. HRSD score > 28 and CGI >
- •Significant current history of autoimmune, endocrine, disorder affecting the brain. No unstable cardiac disease, uncontrolled hypertension or sleep apnea.
- •Changes in psychotropic medications for 2 weeks prior to study entry amd unable to maintain stable doses throughout the trial.
- •Subject has active suicide plan, or history of suicide attempt within the past 12 months.
- •Pregnancy or positive serum pregnancy test.
- •Having a pacemaker
- •History of: skull fracture, craniotomy, deep brain stimulation, cochlear implants, dorsal column pacemaker, cardiac pacemaker, seizures or epilepsy.
结局指标
主要结局
Change From Baseline in Mean Beck Depression Inventory (BDI) Score at Week 2
时间窗: Baseline to Week 2
BDI is a validated, self-report measure used to assess the level of depression symptom severity. BDI values range from 0 (normal) to 63 (extreme depression). Mean Change = (Week 2 Mean Score - Baseline Mean Score).
次要结局
- Change From Baseline in Mean Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Score at Week 2(Baseline to Week 2)
- Change From Baseline in Mean Clinical Global Impressions Illness Severity (CGI-S) Score at Week 2(Baseline to Week 2)
